Prevalence and risk factors for extended spectrum beta-lactamase-producing uropathogens in patients with urinary tract infection

Korean Journal of Urology

Volumn 51, Issue 7, 2010, Pages 492-497

  Lee, Dong Sup ^a   Lee, Chung Bum ^a   Lee, Seung Ju ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Beta lactamases; Cephalosporins; Prevalence; Risk factors

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CEFACLOR; CEFAZOLIN; CEFMINOX; CEFOTAXIME; CEFOTETAN; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CIPROFLOXACIN; COTRIMOXAZOLE; EXTENDED SPECTRUM BETA LACTAMASE; IMIPENEM;

ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BLADDER CATHETERIZATION; DRUG USE; ESCHERICHIA COLI; FEMALE; GENDER; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PREVALENCE; RISK FACTOR; URINARY TRACT INFECTION; UROLOGIC SURGERY;

EID: 77954973647     PISSN: 20056737     EISSN: 20056745     Source Type: Journal    
DOI: 10.4111/kju.2010.51.7.492     Document Type: Article

References (30)

1. Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ, Stamm WE. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin Infect Dis 1999;29:745-58.
2. Colodner R, Kometiani I, Chazan B, Raz R. Risk factors for community-acquired urinary tract infection due to quinolone-resistant E. coli. Infection 2008;36:41-5.
3. National Institute of Public Health and the Environment. European Antimicrobial Resistance Surveillance System (EARSS) annual report 2008. Bilthoven: The Institue; 2009.
4. Karlowsky JA, Jones ME, Thornsberry C, Critchley I, Kelly LJ, Sahm DF. Prevalence of antimicrobial resistance among urinary tract pathogens isolated from female outpatients across the US in 1999. Int J Antimicrob Agents 2001;18:121-7.
5. Zhanel GG, Hisanaga TL, Laing NM, DeCorby MR, Nichol KA, Palatnik LP, et al. Antibiotic resistance in outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA). Int J Antimicrob Agents 2005;26:380-8.
6. Neu HC. The crisis in antibiotic resistance. Science 1992;257:1064-73.
7. Baraff LJ, Ablon WD. Cefaclor versus ampicillin for outpatient treatment of urinary tract infections. Am J Emerg Med 1984;2:327-30.
8. Naber KG. Cefotaxime in urinary tract infections. Infection 1989;17:425-8.
9. Knothe H, Shah P, Krcmery V, Antal M, Mitsuhashi S. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection 1983;11:315-7.
10. Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for beta-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 1995;39:1211-33.
11. Coque TM, Baquero F, Canton R. Increasing prevalence of ESBL-producing Enterobacteriaceae in Europe. Euro Surveill 2008;13.
12. Stamm WE. Catheter-associated urinary tract infections: epidemiology, pathogenesis, and prevention. Am J Med 1991;91:65S-71.
13. National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004;32:470-85.
14. Ryu KH, Kim MK, Jeong YB. A recent study on the antimicrobial sensitivity of the organisms that cause urinary tract infection. Korean J Urol 2007;48:638-45.
15. Lee SJ, Lee SD, Cho IR, Sim BS, Lee JG, Kim CS, et al. Antimicrobial susceptibility of uropathogens causing acute uncomplicated cystitis in female outpatients in South Korea: a multicentre study in 2002. Int J Antimicrob Agents 2004;24(Suppl 1):S61-4.
16. Kim ME, Ha US, Cho YH. Prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in female outpatients in South Korea: a multicentre study in 2006. Int J Antimicrob Agents 2008;31(Suppl 1):S15-8.
17. Lee SJ. Current status of antimicrobial resistance among bacterial pathogens causing urinary tract infection in Korea. Korean J UTII 2009;4:37-44.
18. Naber KG, Schito G, Botto H, Palou J, Mazzei T. Surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): implications for empiric therapy. Eur Urol 2008;54:1164-75.
19. Kader AA, Kumar A. Prevalence and antimicrobial susceptibility of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a general hospital. Ann Saudi Med 2005;25:239-42.
20. Rodriguez-Bano J, Pascual A. Clinical significance of extended-spectrum beta-lactamases. Expert Rev Anti Infect Ther 2008;6:671-83.
21. Calbo E, Romani V, Xercavins M, Gomez L, Vidal CG, Quintana S, et al. Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases. J Antimicrob Chemother 2006;57:780-3.
22. Ortega M, Marco F, Soriano A, Almela M, Martinez JA, Munoz A, et al. Analysis of 4758 Escherichia coli bacteraemia episodes: predictive factors for isolation of an antibiotic-resistant strain and their impact on the outcome. J Antimicrob Chemother 2009;63:568-74.
23. Azap OK, Arslan H, Serefhanoglu K, Colakoglu S, Erdogan H, Timurkaynak F, et al. Risk factors for extended-spectrum beta-lactamase positivity in uropathogenic Escherichia coli isolated from community-acquired urinary tract infections. Clin Microbiol Infect 2010;16:147-51.
24. Rodriguez-Bano J, Navarro MD, Romero L, Martinez-Martinez L, Muniain MA, Perea EJ, et al. Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients. J Clin Microbiol 2004;42:1089-94.
25. Siegel JD, Rhinehart E, Jackson M, Chiarello L; Healthcare Infection Control Practices Advisory Committee. Management of multidrug-resistant organisms in health care settings, 2006. Am J Infect Control 2007;35(10 Suppl 2):S165-93.
26. Goossens H, Ferech M, Vander Stichele R, Elseviers M; ESAC Project Group. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet 2005;365:579-87.
27. Nicolle LE, Bradley S, Colgan R, Rice JC, Schaeffer A, Hooton TM, et al. Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. Clin Infect Dis 2005;40:643-54.
28. Platt R, Polk BF, Murdock B, Rosner B. Risk factors for nosocomial urinary tract infection. Am J Epidemiol 1986;124:977-85.
29. Bukhari SS, Sanderson PJ, Richardson DM, Kaufman ME, Aucken HM, Cookson BD. Endemic cross-infection in an acute medical ward. J Hosp Infect 1993;24:261-71.
30. Tenke P, Kovacs B, Bjerklund Johansen TE, Matsumoto T, Tambyah PA, Naber KG. European and Asian guidelines on management and prevention of catheter-associated urinary tract infections. Int J Antimicrob Agents 2008;31(Suppl 1):S68-78.